Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39

Benzinga · 2d ago
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $38 to $39.